ProShares Ultra Nasdaq Biotechnology (BIB)
| Assets | $86.87M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | $0.04 |
| Dividend Yield | 0.07% |
| Ex-Dividend Date | Dec 20, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | -0.51% |
| Volume | 16,848 |
| Open | 58.57 |
| Previous Close | 58.22 |
| Day's Range | 56.96 - 58.57 |
| 52-Week Low | 40.10 |
| 52-Week High | 63.50 |
| Beta | n/a |
| Holdings | 235 |
| Inception Date | Apr 8, 2010 |
About BIB
Fund Home PageThe ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.
Top 10 Holdings
150.25% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ BIO INDEX SWAP BNP | n/a | 34.23% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | n/a | 32.04% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | n/a | 25.99% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | n/a | 20.58% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | n/a | 11.95% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.85% |
| Amgen Inc. | AMGN | 5.45% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.44% |
| Gilead Sciences, Inc. | GILD | 5.40% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP MORGAN STANLEY & CO. INTERNATIONAL PLC | n/a | 3.32% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2023 | $0.03839 | Dec 28, 2023 |
| Dec 22, 2022 | $0.01985 | Dec 30, 2022 |
| Sep 21, 2010 | $0.011 | Sep 28, 2010 |
News
Cap-Weighting Crucial When Indexing Biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in develo...
How to Invest in Biotech in 2022
It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to o...
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. Thi...
Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that offic...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be...
As Covid Cases Mutate, the Biotech Industry Works to Keep Up
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt t...